Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Evkeeza Coverage Update Prior Auth | Op…
    Ask Trek AI about this page
    CurrentCareSourcePolicy Arkansas PASSE

    Evkeeza (evinacumab-dgnb) — Coverage Criteria for Homozygous Familial Hypercholesterolemia (HoFH)

    Customize your policy alerts

    Sign up for CareSource Policy Arkansas PASSE alerts

    Get alerted when Policy Arkansas PASSE changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior-authorization medical benefit coverage of Evkeeza (evinacumab-dgnb) for members with homozygous familial hypercholesterolemia (HoFH) in Arkansas PASSE. It describes initial and reauthorization clinical criteria, required documentation, dosing, and coverage stance.

    Policy Summary
    PayerCareSource
    PolicyEvkeeza (evinacumab-dgnb) — Coverage Criteria for HoFH
    Policy CodePolicy Arkansas PASSE
    Change TypeCriteria and threshold revisions
    Effective DateApr 1, 2026
    Last ReviewOct 3, 2025
    Next Review Date
    Key ActionObtain prior authorization with documentation of baseline LDL‑C within 90 days, specialist prescribing or consultation, required 8‑week trials of statin+ezetimibe and PCSK9 (unless exceptions), and labs showing ≥15% LDL‑C reduction for reauthorization.
    SourceLink
    POLICY UPDATE CHANGES

    Changed LDL threshold for diagnostic consideration to >400 mg/dL and specified at least 15% LDL reduction for reauthorization.

    Updated age limit and J-code information in prior revisions.

    1 yearminimum eligible age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    15 mg/kg
    dosage per infusion
    monthlydosing interval
    6 monthsinitial approval
    12 monthsreauthorization

    Coverage Criteria for Evkeeza (evinacumab-dgnb)

    Initial Therapy

    Covered when ALL of the following are met:

    Initial Authorization for HoFH: 1) Member is at least 1 year of age;
    Prescriber: 2) Medication prescribed by or in consultation with a lipid specialist or cardiologist;
    Prior lipid-lowering therapy (step therapy): 5) Member unable to achieve LDL-C goal after 8-week trials with ALL of the following: (a) high-intensity or max‑tolerated statin in combination with ezetimibe (unless documented statin intolerance or contraindication); AND (b) PCSK9 inhibitor unless there is evidence of absent LDL receptor function (receptor‑negative HoFH) or the member does not meet the labeled age for PCSK9 inhibitors;
    Adjunct therapy: 6) Evkeeza will be used as an adjunct to other lipid‑lowering treatments (e.g., statin, ezetimibe, PCSK9 inhibitor, LDL apheresis) unless contraindicated or intolerant;
    Lifestyle attestation: 7) Prescriber attests that the member will adhere to a low‑fat diet and exercise regimen;
    Juxtapid timing: 8) Evkeeza is not being concomitantly initiated with Juxtapid (they may not be started at the same time);
    Dosing limit: 9) Dosage allowed / quantity limit: 15 mg/kg IV infusion once monthly;

    If all requirements met, approve for 6 months.

    Continuation Therapy / Reauthorization

    Covered for continuation when ALL of the following are met:

    Reauthorization: 1) Chart notes/laboratory results demonstrate at least a 15% reduction in LDL‑C since starting Evkeeza.>=15% LDL-C reduction

    If met, approve for an additional 12 months.

    CareSource considers Evkeeza (evinacumab-dgnb) not medically necessary for the treatment of conditions that are not listed in this document. Off‑label uses of Evkeeza should be evaluated against the plan’s Off‑Label policy and require documentation supporting the medical necessity for that specific indication.

    Specifically, use of Evkeeza for indications other than homozygous familial hypercholesterolemia (HoFH) as defined in this policy is not medically necessary. The policy’s reauthorization and initial‑coverage criteria apply only to HoFH; requests for other diagnoses will be denied unless the Off‑Label policy justification is provided and approved.

    Coding, Thresholds, and Response Metrics

    Billing code historymixed
    J-codeUpdated J code referenced in policy history (specific J-code not listed in document)
    inv-06: Baseline LDL-C diagnostic threshold
    Baseline LDL-C diagnostic threshold> 400 mg/dL
    Context for thresholdApplies to pre-treatment LDL-C for clinical diagnosis pathway of HoFH
    Documentation timingBaseline LDL-C must be documented within the past 90 days
    inv-07: Reauthorization LDL-C response
    Required LDL-C response for reauthorization>= 15% LDL-C reduction since starting Evkeeza
    Evidence requiredChart notes and laboratory results must document the percent reduction

    Provider Requirements and Documentation

    Prior Authorization

    Prior Authorization Required

    Evkeeza (evinacumab-dgnb) is covered under the medical benefit and requires prior authorization.

    • Benefit type: Medical
    • Prior authorization required
    • Prescriber specialty: Must be prescribed by or in consultation with a lipid specialist or cardiologist
    Step Therapy

    Required Prior Lipid‑Lowering Therapy

    Before initiating Evkeeza, members must have documented trials of intensive lipid-lowering therapy unless an exception applies. Trials must be for at least 8 weeks.

    • High-intensity or max-tolerated statin in combination with ezetimibe (unless documented contraindication to all statins or intolerance to at least 2 different statins, including low/moderate intensity or alternate dosing) — 8-week trial required
    • PCSK9 inhibitor (e.g., evolocumab or alirocumab) — 8-week trial required unless there is evidence of no LDL receptor function (receptor‑negative HoFH) or the member does not meet the labeled age for PCSK9 inhibitors

    Initial Approval Criteria

    Initial therapy

    Covered when ALL of the following are met:

    Eligible population: 1) Member is at least 1 year of age and has a diagnosis of homozygous familial hypercholesterolemia (HoFH);
    Prescriber: 2) Medication prescribed by or in consultation with a lipid specialist or cardiologist;
    HoFH confirmation: 3) HoFH confirmed by genetic testing with two mutant alleles in LDLR, Apo‑B, PCSK9, or LDLRAP1 OR LDL‑C > 400 mg/dL pre‑treatment plus at least one of: (i) cutaneous or tendon xanthoma before age 10; and/or (ii) evidence of heterozygous FH in both parents;
    Baseline LDL-C: 4) Baseline LDL‑C above goal documented within the past 90 days;

    Reauthorization / Continuation Requirements

    Reauthorization requirement

    Reauthorization requires demonstrated LDL‑C reduction.

    Demonstrated response: 1) Documented LDL‑C reduction of at least 15% from baseline since initiation of Evkeeza;>=15% LDL-C reduction

    If met, approve for an additional 12 months.

    Step Therapy / Prior Treatment Requirements

    StepRequired trialDurationExceptions
    1High-intensity or max-tolerated statin in combination with ezetimibe8 weeksDocumented statin intolerance or contraindication
    2PCSK9 inhibitor (e.g., Repatha or Praluent)8 weeksReceptor‑negative HoFH or member below labeled age for PCSK9 inhibitor

    Dosing and Quantity Limits

    inv-17: Evkeeza (evinacumab-dgnb) — dosing key value (15 mg/kg per infusion)
    Dose per infusion15 mg/kg per IV infusion
    Dosing intervalOnce monthly (IV infusion)
    Quantity limit statementDosage allowed/Quantity limit: 15 mg/kg IV infusion once monthly

    Site of Care and Administration

    Billing Rule

    Infusion center (medical benefit) — site‑of‑care note

    Evkeeza is administered as an IV infusion under the medical benefit and should be delivered in an appropriate infusion setting; site‑of‑care and billing should reflect an IV infusion (15 mg/kg once monthly).

    • Dose/quantity limit: 15 mg/kg IV once monthly.
    • Document infusion center or other medical infusion site on the claim/authorization.

    Definitions and Diagnostic Criteria

    inv-13: HoFH diagnostic criteria
    Genetic confirmationGenetic testing showing two mutant alleles in LDLR, Apo-B, PCSK9, or LDLRAP1
    Clinical diagnostic alternativeLDL-C > 400 mg/dL before lipid‑lowering therapy plus at least one of: (a) cutaneous or tendon xanthoma before age 10 and/or (b) evidence of heterozygous FH in both parents
    Age requirement noteApplies within initial authorization criteria for members ≥ 1 year of age

    Background

    Evkeeza (evinacumab‑dgnb) is an angiopoietin‑like 3 (ANGPTL3) inhibitor approved as an adjunct to diet, exercise, and other LDL‑C–lowering therapies to reduce LDL‑C in patients with homozygous familial hypercholesterolemia (HoFH). The agent lowers LDL, HDL, and triglycerides and is the first therapy in its class; within this policy Evkeeza is covered only as adjunctive therapy for HoFH when the documented clinical criteria are met.

    Policy Summary
    PayerCareSource
    PolicyEvkeeza (evinacumab-dgnb) — Coverage Criteria for HoFH
    Policy CodePolicy Arkansas PASSE
    Change TypeCriteria and threshold revisions
    Effective DateApr 1, 2026
    Last ReviewOct 3, 2025
    Next Review Date
    Key ActionObtain prior authorization with documentation of baseline LDL‑C within 90 days, specialist prescribing or consultation, required 8‑week trials of statin+ezetimibe and PCSK9 (unless exceptions), and labs showing ≥15% LDL‑C reduction for reauthorization.
    SourceLink
    On This Page
    Coverage Criteria for Evkeeza (evinacumab-dgnb)Coding, Thresholds, and Response MetricsProvider Requirements and DocumentationInitial Approval CriteriaReauthorization / Continuation RequirementsStep Therapy / Prior Treatment RequirementsDosing and Quantity LimitsSite of Care and AdministrationDefinitions and Diagnostic CriteriaBackground
    If met
    Medication approved for additional 12 months
  1. Evkeeza is used as an adjunct to other lipid-lowering treatments (statin, ezetimibe, PCSK9 inhibitor, LDL apheresis) unless contraindicated or intolerant
  2. Documentation Required

    Required Documentation

    Document the clinical information that supports the diagnosis and prior therapy requirements. Chart notes must include baseline laboratory and diagnostic evidence and attestations.

    • Baseline LDL‑C documented within the past 90 days and above goal (e.g., adults <70 mg/dL or <55 mg/dL with additional ASCVD risk; children <115 mg/dL considered goal thresholds)
    • Genetic testing confirming two mutant alleles in LDLR, APOB, PCSK9, or LDLRAP1 OR diagnostic evidence of HoFH (LDL‑C >400 mg/dL pre‑treatment plus clinical findings such as cutaneous/tendon xanthoma before age 10 or evidence of heterozygous FH in both parents)
    • Documentation of 8‑week trials of required lipid‑lowering therapies or documented contraindications/intolerance as noted
    • Prescriber specialty or documented consultation with a lipid specialist or cardiologist
    • Prescriber attestation that the member will adhere to a low‑fat diet and exercise regimen
    • Dosage/quantity: 15 mg/kg IV infusion once monthly
    Denial Risk

    Triggers for Denial

    Requests that do not meet the policy requirements are at risk for denial.

    • Member does not meet HoFH criteria (no genetic confirmation or insufficient diagnostic evidence)
    • Age <1 year
    • Prescriber is not a lipid specialist or cardiologist and no documented consultation exists
    • Missing baseline LDL‑C within the past 90 days or baseline LDL‑C not above goal
    • Missing documentation of 8‑week trials of statin+ezetimibe and PCSK9 inhibitor (or appropriate documented exceptions)
    • Concomitant initiation with Juxtapid at the same time may be a basis for clarification — policy specifies Evkeeza is not being concomitantly initiated with Juxtapid
    Prior therapy requirements: 5) Failure to achieve LDL‑C goal after 8‑week trials of BOTH: (a) high‑intensity or max‑tolerated statin plus ezetimibe (unless documented statin intolerance/contraindication); AND (b) PCSK9 inhibitor unless receptor‑negative HoFH or age excludes PCSK9 use;
    Adjunct use: 6) Evkeeza to be used as adjunct to other lipid‑lowering therapies unless contraindicated or intolerant;
    Lifestyle: 7) Prescriber attests to adherence to a low‑fat diet and exercise;
    Juxtapid: 8) Evkeeza is not being started concurrently with Juxtapid;
    Dose: 9) Dose limit: 15 mg/kg IV once monthly;

    If all requirements met, approve for 6 months (initial).